scholarly journals SAFETY AND EFFICACY OF ESLICARBAZEPINE ACETATE (ZEBINIX) IN EVERYDAY CLINICAL PRACTICE USING A RETROSPECTIVE MULTICENTRE AUDIT

2014 ◽  
Vol 85 (10) ◽  
pp. e4.180-e4 ◽  
Author(s):  
S Keogh ◽  
P McDonald ◽  
C Lawthom ◽  
MJ Brodie ◽  
B McLean ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Eslicarbazepine Acetate ◽  
Everyday Clinical Practice ◽  
Safety And Efficacy

THUR 058 Eslicarbazepine acetate as monotherapy in clinical practice

2018 ◽  
Vol 89 (10) ◽  
pp. A7.1-A7
Author(s):  
McMurray Rob ◽  
Delanty Norman ◽  
Villanueva Vicente
Keyword(s):  
Clinical Practice ◽  
Adverse Events ◽  
Seizure Frequency ◽  
Adjunctive Therapy ◽  
Pooled Analysis ◽  
Responder Rate ◽  
Seizure Freedom ◽  
European Studies ◽  
Eslicarbazepine Acetate ◽  
Everyday Clinical Practice

PurposeTo assess eslicarbazepine acetate (ESL) as monotherapy in everyday clinical practice.MethodEuro-Esli was a pooled analysis of 14 European studies. In a subanalysis, data were compared for patients treated initially with ESL monotherapy versus adjunctive therapy, and for patients treated at last visit with ESL monotherapy versus adjunctive therapy.Assessments included responder rate (≥50% seizure frequency reduction), seizure freedom rate (seizure freedom at least since prior visit) and incidence of adverse events (AEs).ResultsESL was used as monotherapy in 88/2045 and 229/1340 patients initially and at last visit, respectively. At 12 months, responder and seizure freedom rates were significantly higher in patients treated initially with ESL monotherapy versus adjunctive therapy (responder: 94.1% versus 74.8%; seizure freedom: 88.2% versus 39.0%), and in patients treated at last visit with ESL monotherapy versus adjunctive therapy (responder: 93.2% versus 70.4%; seizure freedom: 77.4% versus 25.9%). Overall incidence of AEs was similar in patients treated initially with ESL monotherapy and adjunctive therapy (29.4% versus 34.4%), and in patients treated at last visit with ESL monotherapy and adjunctive therapy (27.1% versus 30.8%).ConclusionESL was significantly more effective when used as monotherapy compared with adjunctive therapy; safety/tolerability was generally comparable.Supported by Eisai

Risks and benefits of research on children: developing an ethical framework to meet children's needs

Clinical Risk ◽  
2008 ◽  
Vol 14 (6) ◽  
pp. 215-217 ◽  
Author(s):  
James Appleyard
Keyword(s):  
Clinical Practice ◽  
Clinical Research ◽  
Dosage Forms ◽  
Essential Medicines ◽  
Ethical Framework ◽  
Everyday Clinical Practice ◽  
Safety And Efficacy ◽  
Risks And Benefits ◽  
The World

Children are put at unnecessary risk in everyday clinical practice by being given medicines whose safety and efficacy have not been adequately researched. The lack of appropriate dosage forms for many ‘essential medicines’ for the main five treatable conditions causing the deaths of 10 million children worldwide under the age of 5 years are a major reason why countries are not achieving their millennium developmental goals. There has been understandable reluctance to undertake the necessary research on children. The reasons for this are reviewed. The existing levels of protection for child subjects worldwide are insufficient. Key principles are suggested both to encourage clinical research and to ensure adequate protection for children around the world.

“Bridging Gaps – Improving Outcomes”: Problem domains in schizophrenia research, treatment and policy

2016 ◽  
Vol 13 (03) ◽  
pp. 118-120
Author(s):  
W. Wölwer ◽  
W. Gaebel ◽  
V. Toeller
Keyword(s):  
Clinical Practice ◽  
Mental Healthcare ◽  
Knowledge Gaps ◽  
Everyday Clinical Practice ◽  
Treatment Gaps ◽  
Different Types

Summary Background: The provision of mental healthcare for patients with schizophrenia is still characterized both by knowledge gaps and by treatment gaps in everyday clinical practice. Aim: This article discusses the different types of treatment gaps in schizophrenia and describes actions taken to overcome these gaps especially in Europe.

Role of implantable loop recorder in the clinical diagnosis of syncope: Results of the introduction of an effective diagnostic tool

2015 ◽  
Vol 156 (15) ◽  
pp. 609-613
Author(s):  
Miklós Somlói ◽  
Emil Toldy-Schedel ◽  
Zoltán Nényei ◽  
Róbert Böszörményi ◽  
János Tomcsányi
Keyword(s):  
Clinical Practice ◽  
Diagnostic Yield ◽  
Diagnostic Algorithm ◽  
Definitive Treatment ◽  
Implantable Loop Recorder ◽  
Everyday Clinical Practice ◽  
Loop Recorder ◽  
Early Application ◽  
Electrocardiographic Monitoring ◽  
The Everyday

Introduction: Extension of electrocardiographic monitoring via loop recorder implantation may increase the diagnostic yield of syncope work-up. Aim: In this retrospective observational study, the authors wanted to evaluate the diagnostic performance of implantable loop recorder in the everyday clinical practice. Method: The authors analyzed the electronically stored data of all patients who underwent loop recorder implantation between 2005 and 2014 in their cardiology department because of recurrent syncope of undetermined origin. Results: There were 52 loop recorder implantations within the study period. During the 167 (±136) days of monitoring, 36 (69.2%) diagnostic events occurred. In two-thirds of events, (46.2% of all monitored patients) a specific arrhythmia diagnosis was reached, allowing definitive treatment in these cases. In this selected population, there was no correlation between age, presence of known high-risk predictors, or accompanying trauma, and the mechanism of syncope. Conclusions: The high diagnostic rate of implantable loop recorder in the everyday clinical practice is in accordance with the findings in prospective clinical studies. This observation supports the early application of loop recorder in the diagnostic algorithm of syncope. Orv. Hetil., 2015, 156(15), 609–613.

Sign in / Sign up

Export Citation Format

Share Document